Logo
x

Search

Subscribe Now

Primary endpoint

AstraZeneca's ALXN1840 Meets its Primary Endpoint in P-III FoCus Trial for the Treatment of Wilson Disease

AstraZeneca's ALXN1840 Meets its Primary Endpoint in P-III FoCus Trial for the Treatment of Wilson Disease

  • August 26, 2021
Biogen's Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease

Biogen's Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease

  • June 17, 2021
AstraZeneca's AZD7442 Fails to Meet its Primary Endpoint in P-III STORM CHASER Study for the Prevention of Symptomatic COVID-19

AstraZeneca's AZD7442 Fails to Meet its Primary Endpoint in P-III STORM CHASER Study for the Prevention of Symptomatic COVID-19

  • June 15, 2021
Novartis' Triple Regimen Fails to Meet the Primary Endpoint in P-III COMBI-i Study for Advanced Melanoma

Novartis' Triple Regimen Fails to Meet the Primary Endpoint in P-III COMBI-i Study for Advanced Melanoma

  • August 25, 2020
Roche's Tecentriq (atezolizumab) + Paclitaxel Fail to Meet the Primary Endpoint in P-III IMpassion131 Study for Patients with Metastatic Triple-Negative Breast Cancer

Roche's Tecentriq (atezolizumab) + Paclitaxel Fail to Meet the Primary Endpoint in P-III IMpassion131 Study for Patients with Meta...

  • August 7, 2020
Roche's Actemra/RoActemra (tocilizumab) Fails to Meet the Primary Endpoint in P-III COVACTA Study for Patients with COVID-19 Associated Pneumonia

Roche's Actemra/RoActemra (tocilizumab) Fails to Meet the Primary Endpoint in P-III COVACTA Study for Patients with COVID-19 Assoc...

  • July 29, 2020
Innovent Reports the Results of Mazdutide (IBI362) in P-III Trial for the Treatment of Adults with Overweight or Obesity

    Innovent Reports the Results of Mazdutide (IBI362) in P-III Trial for the Treatment of Adults with Overweight or Obesity

    • January 9, 2024
    Agios Pharmaceuticals Reports the Results for Pyrukynd (mitapivat) in P-III Trial to Treat of Non-Transfusion-Dependent Alpha- or Beta-Thalassemia

      Agios Pharmaceuticals Reports the Results for Pyrukynd (mitapivat) in P-III Trial to Treat of Non-Transfusion-Dependent Alpha- or...

      • January 4, 2024
      Alvotech Reports Topline Results from the Study of AVT06 (Biosimilar, Eylea) for Eye Disorders

        Alvotech Reports Topline Results from the Study of AVT06 (Biosimilar, Eylea) for Eye Disorders

        • January 3, 2024
        Jennifer Davidson Highlights the Data from the Phase 3 QUASAR Induction Study 1

          Jennifer Davidson Highlights the Data from the Phase 3 QUASAR Induction Study 1

          • November 13, 2023
          Anand Patel, CMO, of Conquest Research and a Principal Investigator Shares Insights from the Significant Benefits of LX9211

            Anand Patel, CMO, of Conquest Research and a Principal Investigator Shares Insights from the Significant Benefits of LX9211

            • June 19, 2023
            Pfizer

              Pfizer's Bacterial Infection Vaccine Failed to Meet its Primary Endpoint in P-III (CLOVER) Study

              • March 1, 2022
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.